Search
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalto be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Endothelin Receptor Antagonists, Endothelin A Receptor AntagonistsGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]
Ensulizole
go.drugbank.com/drugs/DB11115ApprovedEnsulizole, also known as 2-phenylbenzimidazole-5-sulfonic acid, is a water-soluble sunscreen agent that absorbs strongly at UV-B wavelengths. It is commonly found in cosmetic products and sunscreen formulas in combination with other UV ...
Mixtures: Radiance Superbe Day Cream Neutral Tan, Nivea For Men Age Defying Face MoisturizerProducts: Covergirl Outlast Stay Fabulous 3in1 Foundation Broad spectrum SPF 20 - 857 Golden Tan, Covergirl Outlast Stay Fabulous 3in1 Foundation Broad spectrum SPF 20 - 860 Classic TanAltretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnIt also acts as a chemosterilant for male houseflies and other insects.
Alclometasone
go.drugbank.com/drugs/DB00240ApprovedAlclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.
Categories: Corticosteroid Hormone Receptor AgonistsMoricizine
go.drugbank.com/drugs/DB00680ApprovedWithdrawnAn antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Chloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedThe safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalThe safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalIt is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. … to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for
Categories: Adrenergic alpha-1 Receptor Antagonists